

Benzazepine Ring Formation *via* an Intramolecular Heck Reaction: Synthetic Application to Chilenine

Kyung-Heon Son, Ji-Young Min, and Guncheol Kim*

Department of Chemistry, College of Natural Sciences, Chungnam National University, Daejeon 305-764, Korea

*E-mail: guncheol@gnu.ac.kr

Received October 29, 2013, Accepted December 11, 2013

Key Words : Heck reaction, Benzazepine, Oxidative cyclization, Chilenine

Benzazepine alkaloids such as chilenine **1** and cephalotaxine **2** have been attractive synthetic targets by many synthetic research groups mainly because of their skeletal challenge (Figure 1).¹ Numerous attractive ways have been developed and most of the synthetic approaches to the skeleton have been focused on the cyclization forming the central 7-membered azepine ring.² There have been several reports of azepine formation through Heck-type reactions, however, only a few synthetic applications to natural alkaloids from the intermediates obtained has been reported.³

As an extension of our development of natural azepine alkaloids,⁴ we wanted to explore an intramolecular Heck reaction with precursor **3** for the formation of 7-membered ring and the transformation to chilenine thereafter. And we expected to apply oxidative conditions for the formation of the 5-membered ring of chilenine from **4** (Scheme 1).

In this communication, we wished to suggest a sequential bicyclization process from intermediate **4** in one pot. The precursor **5** would be prepared concisely from **4** which would be prepared concisely from the known compounds (Scheme 1).^{5,6}

For the preliminary investigation of the desired cyclization, we prepared bromide precursor **5** to make a model compound **6**.⁵ From several trials, an applicable condition could be





Figure 1



Scheme 1

Table 1. Heck reaction conditions for the cyclization of **5**


Entry	Palladium (equiv)	Conditions (140 °C in sealed tube)	Yield ^a (%) of 6
1	Pd(dppf)Cl ₂ (0.1 equiv.)	DBU (2 equiv.), THF, 14 h	13%
2	Pd(dppf)Cl ₂ (0.1 equiv.)	DIEA (2 equiv.), DMF, 10 h	14%
3	Pd(dppf)Cl ₂ (0.1 equiv.)	DBU (2 equiv.), DMF, 16 h	42%
4	Pd(dppf)Cl ₂ (0.1 equiv.)	Et ₃ N (2 equiv.), THF, 16 h	72%
5	Pd(PPh ₃) ₄ (0.1 equiv.)	DBU (2 equiv.), THF, 12 h	11%










^aIsolated yield.


selected (entry 4) (Pd(dppf)Cl₂, Et₃N, THF in pressure tube at 140 °C) (Table 1).

The scope and the limit of this reaction have been searched (Table 2). The condition using Hunig's base instead of Et₃N afforded better results for the related derivatives. Depending on allylic moieties on amide, the ratio of double bond in *exo* or *endo* position of the product has varied (entry 3, 6, 7) and the yields were ranged from moderate to good (15% to 76%).

Synthetic application to chilenine was readily tried the requisite molecule **3**.⁶ The Heck reaction condition selected in Table 1 yielded azepine **4** in 67% yield. The next cyclization of **5** or the benzoyl azepin-5-one intermediate formed by oxidative cleavage of the *exo*-methylene group has failed, so the desired oxidative cyclization was performed from the enol lactone **17** to afford **18**, a known precursor for chilenine.⁷ Compound **17** was prepared by dihydroxylation with OsO₄ followed by oxidative cleavage to ketone, and *O*-acylation of the ketone with Ac₂O under heating at 90 °C in DMF in the presence of excess DBU (64% yield for the three step sequence).⁸ Compound **17** was found to be tenacious against cyclization as well as oxidation, only forcing condition (2-3 equiv. Pa(OAc)₂ with or without co-oxidant benzoquinone in refluxing CH₃CN overnight) enabled the conversion to allow 30 to 36% yields of **18**.⁹ The final transformation of **18** to chilenine has been repeated by the known procedure, dihydroxylation using OsO₄ followed by H₂S treatment, suggesting a new way to a concise formal

Table 2. Cyclization study of **7**


Entry	Product
1	 8 : 40%
2	 9 : 34%
3	 10 : 45%
3	 11 : 17%
3	 12 : 55%
4	 13 : 20% (single isomer)
4	 14 : 15% (single isomer)
5	 15 : 76% (single isomer)
7	 16 : 75% (single isomer)

**Scheme 2**

synthesis of chilenine.

In summary, a palladium-catalyzed cyclization reaction of aryl halides containing allylic moiety provided azepine skeletons, and the following manipulation including an oxidative cyclization allowed a concise route to chilenine.

Acknowledgments. This work was supported by the Korea Research Foundation Grant funded by Korean Government (KRF-2011-0015865).

References and Notes

- Chilenine: (a) Cordell, G. A. In *The Alkaloids: Chemistry and Pharmacology*; Academic Press: San Diego, 1998; Vol. 50. (b) Weinstock, J.; Hieble, J. P.; Wilson, J. W. *Drugs Future* **1985**, *10*, 645-651. (c) Padwa, A.; Beall, L. S.; Eidell, C. K.; Worsencroft, K. J. *J. Org. Chem.* **2001**, *66*, 2414-2421. Cephalotaxine: (a) Huang, L.; Xue, Z. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: New York, **1984**; Vol. 23, pp 157-226. (b) Hudlicky, T.; Kwart, L. D.; Reed, J. W. In *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; John Wiley and Sons: New York, **1987**; Vol. 5, pp 639-690.
- Chilenine: (a) Kim, G.; Lee, K. Y.; Yoo, C.-H. *Synth. Commun.* **2008**, *38*, 3251-3259. (b) Fuwa, H.; Sasaki, M. *Heterocycles* **2008**, *76*, 521-539. (c) Onozaki, Y.; Kurono, N.; Senboku, H.; Tokuda, M.; Orito, K. *J. Org. Chem.* **2009**, *74*, 5486-5495. (d) Piko, B. E.; Keegan, A. L.; Leonard, M. S. *Tetrahedron Lett.* **2011**, *52*, 1981-1982. Cephalotaxine: (a) Esmieu, W. R.; Worden, S. M.; Catterick, D.; Wilson, C.; Hayes, C. J. *Org. Lett.* **2008**, *10*, 3045-3048. (b) Taniguchi, T.; Ishibashi, H. *Org. Lett.* **2008**, *10*, 4129-4131. (c) Sun, M.-r.; Lu, H.-t.; Wang, Y.-z.; Yang, H.; Liu, H.-m. *J. Org. Chem.* **2009**, *74*, 2213-2216. (d) Li, W.-D. Z.; Duo, W.-G.; Zhuang, C.-H. *Org. Lett.* **2011**, *13*, 3538-3541. (e) Zhang, Q.-W.; Xiang, K.; Tu, Y.-Q.; Zhang, S.-Y.; Zhang, X.-M.; Zhao, Y.-M.; Zhang, T.-C. *Chem. Asian J.* **2012**, *7*, 894-898. (f) Zhang, Z.-W.; Zhang, X.-F.; Feng, J.; Yang, Y.-H. Wang, C.-C.; Feng, J.-C.; Liu, S. *J. Org. Chem.* **2013**, *78*, 786-790.
- (a) García, A.; Rodríguez, D.; Castedo, L.; Saá, C.; Domínguez, D. *Tetrahedron Lett.* **2001**, *42*, 1903-1905. (b) Kim, G.; Kim, J. H.; Kim, W.-J.; Kim, Y. A. *Tetrahedron Lett.* **2003**, *44*, 8207-8209. (c) Arnold, L. A.; Luo, W.; Guy, R. K. *Org. Lett.* **2004**, *6*, 3005-3007. (d) Beebe, X.; Gracias, V.; Djuric, S. W. *Tetrahedron Lett.* **2006**, *47*, 3225-3228.
- (a) Kim, G.; Jung, P.; Tuan, L. A. *Tetrahedron Lett.* **2008**, *49*, 2391-2392. (b) Oh, K. R.; Kim, G. *Bull. Korean Chem. Soc.* **2012**, *33*, 3933-3934. (c) Kim, H. D.; Kim, G. *Tetrahedron Lett.* **2013**, *54*, 1765-1767.
- Bomination of 3,4-dimethoxyphenethylamine in acetic acid (85%), benzoylation with 2,3-dimethoxybenzoyl chloride (92%), and allylation with allyl bromide in the presence of NaH and Bu₄NBr (95%) provided **5**.
- Katritzky, A. R.; He, H.-Y.; Jiang, T. *Tetrahedron Lett.* **2002**, *43*, 2831-2833.
- Fang, F. G.; Danishefsky, S. J. *Tetrahedron Lett.* **1989**, *30*, 2747-2750.
- Compound **17**: ¹H NMR (400 MHz, CDCl₃) δ 7.65 (s, 1H), 7.14-7.10 (m, 2H), 7.00-7.97 (m, 2H), 6.84-6.80 (m, 3H), 6.70 (s, 1H), 6.68 (s, 1H), 6.52 (s, 1H), 6.47 (s, 1H), 5.96 (s, 2H), 5.94 (s, 2H), 4.19 (m, 2H), 3.90 (s, 3H), 3.84-3.76 (m, 7H), 3.57 (m, 1H), 3.08 (m, 2H), 2.99-2.96 (m, 2H), 2.29 (s, 3H), 2.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 170.2, 167.7, 166.9, 152.9, 152.8, 147.5, 147.4, 146.9, 146.8, 145.5, 145.2, 134.2, 133.7, 133.4, 132.0, 130.5, 130.3, 126.3, 125.1, 124.7, 121.6, 119.5, 119.2, 118.8, 113.9, 113.6, 109.5, 105.3, 105.1, 101.4, 61.7, 61.5, 55.9, 50.3, 48.2, 35.6, 34.1, 20.9.
- Compound **18**: ¹H NMR (400MHz, CDCl₃) δ 7.54 (d, *J* = 8.5 Hz, 1H), 7.12 (d, *J* = 8.6 Hz, 1H), 6.91 (s, 1H), 6.68 (s, 1H), 5.98 (s, 2H), 4.07 (s, 3H), 3.93 (s, 3H), 3.91-3.96 (bm, 2H), 3.07 (m, 2H), 2.45 (s, 3H); ¹³C NMR (100MHz, CDCl₃) δ 169.5, 163.6, 153.4, 148.1, 147.4, 147.3, 134.4, 130.3, 129.0, 127.6, 126.9, 121.3, 119.6, 116.6, 109.9, 105.6, 101.6, 62.5, 56.7, 43.3, 34.8, 21.4.